M&A activity
From JP Morgan to the Next Wave: What’s Driving Biotech in 2026
J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science
Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected
Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy